| Page 13 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Author(s):

de Castro CM, Patel BJ

Primary Author:

de Castro CM

Journal Title:

Expert Opinion on Pharmacotherapy

Original Publication Date:

Oct 2024

Introduction: Standard-of-care first-line treatments for

Bone Marrow Disease(s):

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten

Author(s):

Risitano AM, Frieri C, Marano L, Urciuoli E, Sanseverino A, Nannelli C, Notaro R

Primary Author:

Risitano AM

Journal Title:

American Journal of Hematology

Original Publication Date:

Oct 2024

Bone Marrow Disease(s):

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Drug development in higher-risk myelodysplastic syndromes

Author(s):

Venugopal S, Sekeres MA

Primary Author:

Venugopal S

Journal Title:

Blood Cancer Journal

Original Publication Date:

Oct 2024

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Treatment of lower-risk myelodysplastic syndromes

Author(s):

Merz AMA, Platzbecker U

Primary Author:

Merz AMA

Journal Title:

Haematologica

Original Publication Date:

Oct 2024

Myelodysplastic neoplasms (MDS) involve clonal hematopoiesis and cellular dysplasia, driven by genetic and epigenetic alterations. Spliceosome mutations and epigenetic dysregulation underscore the intricate pathogenesis of MDS. The

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes Treatment (PDQ®): Patient Version

Author(s):

PDQ Adult Treatment Editorial Board

Primary Author:

PDQ Adult Treatment Editorial Board

Journal Title:

PDQ Cancer Information Summaries

Original Publication Date:

Oct 2024

This PDQ cancer information summary has current information about the treatment of

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology

Author(s):

Della Porta MG, Bewersdorf JP, Wang YH, Hasserjian RP

Primary Author:

Della Porta MG

Journal Title:

Histopathology

Original Publication Date:

Oct 2024

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Diagnosis of myelodysplastic syndromes: the classic and the novel

Author(s):

Oster HS, Van de Loosdrecht AA, Mittelman M

Primary Author:

Oster HS

Journal Title:

Haematologica

Original Publication Date:

Oct 2024

The

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Author(s):

Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM

Primary Author:

Bidikian A

Journal Title:

Expert Review of Anticancer Therapy

Original Publication Date:

Oct 2024

Introduction:

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature

Author(s):

Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD

Primary Author:

Nasnas P

Journal Title:

Clinical Lymphoma, Myeloma & Leukemia

Original Publication Date:

Oct 2024

Bone Marrow Disease(s):

Family reflections: pediatric aplastic anemia research; a parent perspective

Author(s):

Georgieff T

Primary Author:

Georgieff T.

Journal Title:

Pediatric Research

Original Publication Date:

Oct 2024

Bone Marrow Disease(s):